Antibody therapy for cancer has potential to combine specific targeting with a range of effector mechanisms to produce potent anti-tumor responses. Antibody-based treatments are growing in success for adult cancers but have shown limited efficacy for pediatric cancers. Pediatric solid tumors have a lower mutation load that their adult counterparts and pose a unique set of challenges compared to hematological malignancies and to adult solid tumors. Whilst a number of antibodies have been subject to clinical trials in pediatric patients the response tends to be limited and there is need to identify patients most likely to benefit. The role of antibodies in combination with conventional chemotherapy and new emerging therapies is a developing field that could provide new opportunities.

用于癌症的抗体疗法具有将特异性靶向与一系列效应器机制相结合以产生有效的抗肿瘤反应的潜力。对于成人癌症，基于抗体的治疗方法正在成功发展，但对儿童癌症的治疗效果却很有限。与血液恶性肿瘤和成年实体瘤相比，小儿实体瘤的突变负荷要比成年实体瘤低，并且构成了一系列独特的挑战。尽管许多抗体已在儿科患者中进行了临床试验，但反应往往有限，需要确定最有可能受益的患者。抗体与常规化学疗法和新兴疗​​法结合的作用是一个可以提供新机会的发展中领域。